272 related articles for article (PubMed ID: 26165838)
1. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.
Tervonen TA; Belitškin D; Pant SM; Englund JI; Marques E; Ala-Hongisto H; Nevalaita L; Sihto H; Heikkilä P; Leidenius M; Hewitson K; Ramachandra M; Moilanen A; Joensuu H; Kovanen PE; Poso A; Klefström J
Oncogene; 2016 Apr; 35(14):1832-46. PubMed ID: 26165838
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
Tervonen TA; Pant SM; Belitškin D; Englund JI; Närhi K; Haglund C; Kovanen PE; Verschuren EW; Klefström J
Cancer Res; 2021 Mar; 81(6):1513-1527. PubMed ID: 33461973
[TBL] [Abstract][Full Text] [Related]
3. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
5. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.
Parr C; Jiang WG
Int J Oncol; 2001 Oct; 19(4):857-63. PubMed ID: 11562767
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
[TBL] [Abstract][Full Text] [Related]
7. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
8. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
12. Augmented expression of hepatocytes growth factor activator inhibitor type 1 (HAI-1) in intrahepatic small bile ducts in primary biliary cirrhosis.
Sasaki M; Ikeda H; Kataoka H; Nakanuma Y
Virchows Arch; 2006 Oct; 449(4):462-71. PubMed ID: 16941151
[TBL] [Abstract][Full Text] [Related]
13. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
14. Hepsin: a multifunctional transmembrane serine protease in pathobiology.
Li S; Wang L; Sun S; Wu Q
FEBS J; 2021 Sep; 288(18):5252-5264. PubMed ID: 33300264
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.
Yamauchi M; Kataoka H; Itoh H; Seguchi T; Hasui Y; Osada Y
J Urol; 2004 Feb; 171(2 Pt 1):890-6. PubMed ID: 14713848
[TBL] [Abstract][Full Text] [Related]
16. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2): Emerging key players in epithelial integrity and cancer.
Kataoka H; Kawaguchi M; Fukushima T; Shimomura T
Pathol Int; 2018 Mar; 68(3):145-158. PubMed ID: 29431273
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor activator inhibitor type‑1 in cancer: advances and perspectives (Review).
Zheng Q; Wu H; Cao J; Ye J
Mol Med Rep; 2014 Dec; 10(6):2779-85. PubMed ID: 25310042
[TBL] [Abstract][Full Text] [Related]
19. Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice.
Hsu YC; Huang HP; Yu IS; Su KY; Lin SR; Lin WC; Wu HL; Shi GY; Tao MH; Kao CH; Wu YM; Martin PE; Lin SY; Yang PC; Lin SW
Hepatology; 2012 Nov; 56(5):1913-23. PubMed ID: 22505209
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
